Most-Read Print Stories of 2022
This year's most-read print stories from our monthly publication include 'Paxlovid Rebound: Rare But Real,' 'Diabetes Medications Find New Life as Weight-Loss Drugs,' 'Health Plans Prepare to Post Prices for Consumers,' and more.
- Paxlovid Rebound: Rare But Real
Mayo Clinic researchers reported today in the journal Clinical Infectious Diseases that less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19.
- Diabetes Medications Find New Life as Weight-Loss Drugs
Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite. But their cost-effectiveness is in question, and many payers are saying no to coverage — for now.
- Childhood Insomnia Symptoms Often Persist into Adulthood, Study Finds
Children with poor sleep had a 2.6-fold higher risk of developing adult insomnia, according to longitudinal research conducted by Penn State researchers.
- Multiple Sclerosis - Some Drugs New, Some Tried-and-True
The race is on to be the first-approved Bruton tyrosine kinase inhibitor. Meanwhile, trials are underway to test statins and metformin as treatments for multiple sclerosis.
- Health Plans Prepare to Post Prices for Consumers
Price-transparency rule allows insurers to cut MLR payments by using incentives to encourage consumers to choose low-cost, high-value providers.